Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Inogen Inc executive Andrew P. Reding, who serves as EVP and COO, filed an initial Form 3 to report his status as an insider of the company. The filing lists no stock purchases, sales, option exercises, or other transactions, serving only as a baseline ownership report.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief HR Officer, sold 10,938 shares of common stock in an open-market transaction on July 1, 2026 at a weighted average price of $6.5959 per share under a pre-arranged Rule 10b5-1 trading plan.
After this sale, she directly holds 5,039 shares of Inogen common stock.
Inogen Inc (INGN) officer Jennifer Yi Boyer gave notice of a proposed sale of 10,938 common shares, with an aggregate market value of $70,550.10 and an approximate sale date of July 1, 2026. The notice lists February 27, 2026 as the plan adoption or instruction date, if relying on Rule 10b5-1. It states that the shares to be sold were acquired upon vesting of restricted stock units on March 1, 2025 and March 1, 2026.
Inogen, Inc. is creating a new Chief Operating Officer role and has appointed Andy Reding, effective July 6, 2026. He will oversee revenue, operations, and cross-functional execution as the company pursues new products and geographic expansion in respiratory care.
Reding’s employment agreement provides a $500,000 annual base salary, a target bonus equal to 70% of salary, and a $100,000 cash sign-on bonus, partially repayable if he departs under certain conditions within two years. Inogen will also reimburse $2,500 of his legal fees related to the agreement.
As an equity inducement, Reding will receive 130,000 time-based RSUs, vesting in three equal annual installments, granted outside existing equity plans under Nasdaq Listing Rule 5635(c)(4). If he is terminated without cause or resigns for good reason, he may receive salary continuation and subsidized medical benefits for 12 months, or 24 months if this occurs around a change of control, subject to a release of claims and other conditions.
Inogen, Inc. reported results of its annual stockholder meeting and changes to its equity compensation plan. Stockholders approved an Amended and Restated 2023 Equity Incentive Plan that increases the shares of common stock available for awards by an additional 750,000 shares, effective upon approval.
Two Class III directors, Glenn Boehnlein and Mira Sahney, were re-elected, and Deloitte & Touche LLP was ratified as independent auditor for the year ending December 31, 2026. Stockholders approved executive compensation on an advisory basis and the equity plan, while an amendment to declassify the board was not approved. About 20,844,941 of 27,324,616 entitled shares were represented, a turnout of approximately 76.28%.
Sahney Mira Kirti reported acquisition or exercise transactions in this Form 4 filing.
Inogen director Mira Kirti Sahney received an equity grant of 28,081 shares of Common Stock through a restricted stock unit award. The grant date was June 5, 2026.
The award vests on the earlier of the one-year anniversary of the grant or the day prior to the next Annual Meeting of stockholders, subject to her continued service. After this grant, she directly holds 67,805 shares of Inogen stock. This is compensation-related, not an open-market purchase.
Jamali Vafa reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Jamali Vafa received a grant of 28,081 shares of common stock as a restricted stock unit award on June 5, 2026, at no cash cost. Following the award, Vafa directly holds 43,081 shares. The restricted stock units vest on the earlier of one year after grant or the day before the next annual stockholder meeting, subject to continued service.
Inogen Inc director Glenn S. Boehnlein received an equity grant of 28,081 shares of Common Stock on June 5, 2026, at no cash cost, reported as acquired pursuant to a restricted stock unit award. The award will vest on the earlier of the one-year anniversary of the grant date or the day before Inogen’s next Annual Meeting of stockholders, subject to his continued service. Following this grant, Boehnlein directly holds 104,966 shares of Inogen common stock.
Rider Heather D. reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Heather D. Rider received an equity grant in the form of restricted stock units. She was awarded 28,081 shares of common stock at no purchase price, bringing her directly held stake to 116,282 shares. According to the award terms, these restricted stock units will vest on the earlier of the one-year anniversary of the grant date or the day before Inogen’s next Annual Meeting of stockholders, as long as she continues in service with the company.
Mora Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Elizabeth Mora received 28,081 shares of common stock as a restricted stock unit award. These RSUs were granted at no cash cost and increase her direct holdings to 107,261 shares. The award will vest after about one year, subject to her continued service.